Dmitri Aleksenko
Neurology · Shreveport, LANPI 1255718946
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.6% of the total across 452 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 23 manufacturers reported payments, led by AbbVie at 28.1% of the total. Reporting peaked in 2021 at $2,008 and has fallen 99.3% since, to $14 in 2025.
Across 452 payments — averaging $13.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Acadia Pharmaceuticals Inc$685
- Sanofi$572
- Amgen$444
- Biohaven Pharmaceuticals, Inc.$444
- AstraZeneca$328
- plus $2K from 17 others
What the payments were for
- Food & beverage$6,185100%
- Education$250%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 185 | $1,742 |
| Acadia Pharmaceuticals Inc | 76 | $685 |
| Sanofi | 26 | $572 |
| Amgen(2 entities) | 27 | $444 |
| Biohaven Pharmaceuticals, Inc. | 16 | $444 |
| AstraZeneca | 12 | $328 |
| Lilly USA, LLC | 16 | $258 |
| Biogen | 14 | $249 |
| Pfizer | 14 | $237 |
| Bristol Myers Squibb | 15 | $216 |
| Genentech USA, Inc. | 10 | $165 |
| Neurocrine Biosciences, Inc. | 8 | $160 |
| Mallinckrodt Hospital Products Inc. | 1 | $114 |
| Biohaven Pharmaceutical Holding Company Ltd. | 6 | $103 |
| Kyowa Kirin, Inc. | 5 | $86 |
| Novartis | 4 | $85 |
| Amneal Pharmaceuticals LLC | 4 | $74 |
| MDD US Operations, LLC | 3 | $59 |
| TG Therapeutics, Inc. | 2 | $42 |
| Lundbeck LLC | 2 | $42 |
| Teva Pharmaceuticals USA, Inc. | 2 | $40 |
| Adamas Pharmaceuticals, Inc. | 2 | $33 |
| Eisai Inc. | 2 | $30 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NURTEC ODT$250
- SOLIRIS$124
- ACTHAR$114
How this compares
$6,209 in reported general payments places this provider in the 60th percentile of 225 neurology providers in Louisiana.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Donepezil Hcl | 21 | $366 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 11 | $162 |
Paid to pharmacies, not to this prescriber.
Other neurology in Shreveport
- Meghan HarrisShreveport$553K
- Erik BurtonShreveport$154K
- Ernest LittleShreveport$52K
- Chaitanya AmrutkarShreveport$17K
- Debra DavisShreveport$16K
- Jenny GuerreShreveport$15K
- Gurleen SikandShreveport$14K
- Kevin CallerameBaton Rouge$420K
- Gerald CaleganBaton Rouge$400K
- Maria Carmen WilsonCovington$295K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.